Soluble urokinase plasminogen activator receptor levels are predictive of COVID-19 severity in Afro-Caribbean patients.
Mael PadelliPapa GueyeDiane GuillouxRishika BanydeenValentine CampanaAndre CabieRemi NevierePublished in: Biomarkers in medicine (2022)
Aim: To investigate association between soluble urokinase plasminogen activator receptor (suPAR) plasma levels at admission and incidence of complications in COVID-19 patients. Patients & methods: We considered Afro-Caribbean patients (n = 64) admitted to the hospital between 1 February 2020 and 28 February 2021. Primary outcome was time from the hospital admission until intensive care unit care or death. Results: Primary outcome (hazard ratio, HR [95%CI]) was associated with higher CT scan severity score (3.18 [1.15-8.78], p = 0.025), National Early Warning Score (NEWS2; 1.43 [1.02-2.02], p = 0.041) and suPAR (1.28 [1.06-2.06], p = 0.041). Kaplan-Meier analysis indicated patients with suPAR level above 8.95 ng/ml had a worse outcome (7.95 [3.33-18.97], p < 0.001). Conclusion: Our study suggests that COVID-19 patients with increased baseline suPAR levels are at a high risk of complications.
Keyphrases
- end stage renal disease
- intensive care unit
- newly diagnosed
- ejection fraction
- sars cov
- chronic kidney disease
- healthcare
- peritoneal dialysis
- prognostic factors
- palliative care
- patient reported outcomes
- chronic pain
- mechanical ventilation
- binding protein
- health insurance
- respiratory syndrome coronavirus
- patient reported
- pet ct
- acute care